Therapeutic Fasting and Immune Aging
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorCentre Hospitalier Universitaire de Saint Etienne
About this trial
Immunosenescence is the age-related decline of the immune system, involving a state of chronic inflammation and a decrease in the diversity/adaptability of the lymphocyte repertoire. The consequences of immunosenescence are multiple, including increased susceptibility to infections and poorer vaccine responses.
Eligibility criteria
Qualifiers
Patient affiliated or entitled to a social security scheme
Residing in a Long-Term Care Unit (LTCU) or a Facility for the Elderly Dependent (EHPAD)
A person deemed a priori, by the geriatrician member of the monitoring committee, to be capable of following the dietary recommendations required for the study.
A person deemed a priori, by the clinician in charge, to be able to follow the dietary recommendations required by the study.
Disqualifiers
Inability and/or unwillingness to follow dietary recommendations and/or perform follow-up examinations required for the study
Iso-resource group 1 or 2 according to the AGGIR grid
BMI < 18.5 kg/m2 or recent weight loss > 5% in 1 month or recent weight loss > 10% in 6 months from previous weight
Albuminemia < 30g/l
Trial design
Treatments tested in this trial
- Fasting mimicking diet (FMD)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov